NY-ESO-1: review of an immunogenic tumor antigen.
In the 9 years since its discovery, cancer-testis antigen NY-ESO-1 has made one of the fastest transitions from molecular, cellular, and immunological description to vaccine and immunotherapy candidate, already tested in various formulations in more than 30 clinical trials worldwide. Its main characteristic resides in its capacity to elicit spontaneous antibody and T-cell responses in a proportion of cancer patients. An overview of immunological findings and immunotherapeutic approaches with NY-ESO-1, as well the role of regulation in NY-ESO-1 immunogenicity, is presented here.
Gnjatic
Sacha
S
Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York 10021, USA.
Nishikawa
Hiroyoshi
H
Jungbluth
Achim A
AA
Güre
Ali O
AO
Ritter
Gerd
G
Jäger
Elke
E
Knuth
Alexander
A
Chen
Yao-Tseng
YT
Old
Lloyd J
LJ
D000951:Antigens, Neoplasm / Q000096:biosynthesis*; D014408:Biomarkers, Tumor; D045744:Cell Line, Tumor; D002986:Clinical Trials as Topic; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins / Q000096:biosynthesis*; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism*
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C104948:CTAG1B protein, human; D008565:Membrane Proteins